ArticleOne health (Amsterdam, Netherlands)2021
Risk of Crimean Congo haemorrhagic fever virus (CCHFV) introduction and spread in CCHF-free countries in southern and Western Europe: A semi-quantitative risk assessment.
Article in One health (Amsterdam, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 54 citations in OpenAlex.
- Mapping one health surveillance and networks for vector-borne disease prevention and control in Europe - A scoping review.One health (Amsterdam, Netherlands) · 2026Review
- Article
- Crimean-Congo Hemorrhagic Fever Virus in Africa: Epidemiological Trends, Transmission Ecology, Hotspot Heterogeneity, and Preparedness Challenges-A Narrative Review.Tropical medicine and infectious disease · 2026Review
- Crimean-Congo Hemorrhagic Fever in Children: Secondary Hemophagocytic Lymphohistiocytosis and Time-course of Biomarkers in a Single-Center Cohort (2019-25).Journal of tropical pediatrics · 2026Article
- Improving Molecular Detection of Tick-Borne Pathogens in Citizen-Collected Ticks.Pathogens (Basel, Switzerland) · 2026Article
- A multisectoral effort against Crimean-Congo hemorrhagic fever: Towards One Health approach implementation in the Balkans and Black Sea region.One health (Amsterdam, Netherlands) · 2025Article
- Assessing the risk of diseases with epidemic and pandemic potential in a changing world.Science advances · 2025Article
- Tick-Borne Viruses in a Changing Climate: The Expanding Threat in Africa and Beyond.Microorganisms · 2025Review
- Serosurveillance of Crimean-Congo hemorrhagic fever virus antibodies in livestock as a reservoir for human infection in Afghanistan.One health (Amsterdam, Netherlands) · 2025Article
- Crimean-Congo hemorrhagic fever: Pathogenesis, transmission and public health challenges.World journal of virology · 2025Review
- Seroprevalence and Risk Factors of Crimean-Congo Hemorrhagic Fever Exposure in Wild and Domestic Animals in Benin.Viruses · 2025Article
- Molecular characterization and phylogenetic analysis of Crimean-Congo hemorrhagic fever virus, northwestern of Iran.BMC infectious diseases · 2025Article
- Mapping the potential suitable habitats for Hyalomma rufipes (Acari: Ixodidae) in Africa and Western Eurasia.PLoS neglected tropical diseases · 2025Article
- Detection of Crimean-Congo hemorrhagic fever virus and Rift Valley fever virus antibodies in animal workers in Cameroon.Frontiers in veterinary science · 2025Article
- Spatial examination of social and environmental drivers of Middle East respiratory syndrome coronavirus (MERS-CoV) across Kenya.EcoHealth · 2024Article
- Vectorial dynamics underpinning current and future tick-borne virus emergence in Europe.The Journal of general virology · 2024Review
- Control strategies for emerging infectious diseases: Crimean-Congo hemorrhagic fever management.Health science reports · 2024Article
- Vaccine approaches and treatment aspects against Crimean Congo hemorrhagic fever.Virusdisease · 2024Review
- Exploratory actor mapping of social interactions within tick risk surveillance networks in France.Current research in parasitology & vector-borne diseases · 2024Article
- Building a pathway to One Health surveillance and response in Asian countries.Science in One Health · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crimean-Congo hemorrhagic fever (CCHF) is a severe tick-borne viral zoonotic disease caused by Crimean-Congo hemorrhagic fever virus (CCHFV). The disease is usually asymptomatic in domestic and wild animals, both of which may act as reservoirs of the virus. CCHF is endemic in parts of Africa, Asia, the Middle East and Eastern Europe. During the last decade, the emergence or re-emergence of CCHF was described in several countries in the Eastern Mediterranean Region, with an increasing risk of extension into new areas. Given the public health importance, this study undertakes a semi-quantitative risk assessment to analyse the likelihood of entry and exposure of CCHFV into 9 CCHF-free countries in Southern and Western Europe. Based on a framework outlining the probability of the virus entry and exposure, the risk estimates were assessed for each individual country. The risk assessment was performed using information from public databases and the available scientific literature. The likelihood of entry was conducted considering 3 main pathways: infected tick vectors, wildlife and livestock. The likelihood of exposure was assessed considering the probability of survival of the infected ticks once introduced in CCHF-free countries (depending on abiotic and biotic factors), and the exposure of resident uninfected susceptible ticks to infected imported wildlife and livestock. The risk estimates (combined CCHFV introduction and exposure) were low for the majority of the countries (Austria, Belgium, Germany, Luxembourg, Netherlands, Slovenia and Switzerland) and medium for France and Italy, if accounting only for animal health consequences. Considering the public health consequences only, the risks were rated low for all the countries, except for Italy where it was assessed to be medium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.